Maftivimab
Jump to navigation
Jump to search
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Human |
Target | Zaire ebolavirus glycoprotein |
Clinical data | |
Pronunciation | maf tiv' i mab |
License data |
|
Drug class | Monoclonal antibody |
ATC code |
|
Identifiers | |
CAS Number | |
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C6368H9886N1706O2008S46 |
Molar mass | 143947.83 g·mol−1 |
Maftivimab is a Zaire ebolavirus glycoprotein-directed human monoclonal antibody that is part of the fixed-dose combination atoltivimab/maftivimab/odesivimab that is used for the treatment of Zaire ebolavirus (Ebola virus).[1][2]
References
- ^ "FDA Approves First Treatment for Ebola Virus". U.S. Food and Drug Administration (FDA) (Press release). 14 October 2020. Retrieved 14 October 2020. This article incorporates text from this source, which is in the public domain.
- ^ "Regeneron's Antibody Cocktail REGN-EB3 (Inmazeb) is First FDA-Approved Treatment for Ebola (Zaire Ebolavirus)". Regeneron Pharmaceuticals Inc. (Press release). 14 October 2020. Retrieved 14 October 2020.
External links
- "Maftivimab". Drug Information Portal. U.S. National Library of Medicine.
- "Statement on a nonproprietary name adopted by the USAN Council USAN (FG-103) Maftivimab" (PDF).
Categories:
- Source attribution
- Articles with short description
- Short description matches Wikidata
- Use American English from October 2020
- All Wikipedia articles written in American English
- Use dmy dates from October 2020
- Drugs not assigned an ATC code
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without InChI source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Drugs that are a monoclonal antibody
- Ebola
- Monoclonal antibodies
- All stub articles
- Antiinfective agent stubs